Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cell Rep Med. 2024 Mar 19;5(3):101474. doi: 10.1016/j.xcrm.2024.101474.
Subvariants of the Omicron lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) efficiently escape neutralizing antibody responses induced by both vaccination and infection with antigenically distinct variants. Here, we describe the potency and breadth of neutralizing and binding antibody responses against a large panel of variants following an Omicron BA.1 or BA.2 breakthrough infection in a heterogeneous cohort of individuals with diverse exposure histories. Both BA.1 and BA.2 breakthrough infections significantly boost antibody levels and broaden antibody reactivity. However, this broader immunity induced by BA.1 and BA.2 breakthrough infections does not neutralize Omicron BQ and XBB subvariants efficiently. While these subvariants are not neutralized well by post-breakthrough sera, suggesting escape, binding non-neutralizing antibody responses are sustained. In summary, our data suggest that while BA.1 and BA.2 breakthrough infections broaden the immune response to SARS-CoV-2 spike, the induced neutralizing antibody response is still outpaced by viral evolution.
奥密克戎谱系严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的亚变体能够有效地逃避由疫苗接种和与具有不同抗原性的变体感染引起的中和抗体反应。在这里,我们描述了在具有不同暴露史的异质个体中,奥密克戎 BA.1 或 BA.2 突破感染后,针对大量变体的中和和结合抗体反应的效力和广度。BA.1 和 BA.2 突破感染均显著提高了抗体水平并拓宽了抗体反应性。然而,BA.1 和 BA.2 突破感染诱导的这种更广泛的免疫并不能有效地中和奥密克戎 BQ 和 XBB 亚变体。尽管这些亚变体不能被突破后血清很好地中和,表明发生了逃逸,但结合非中和抗体反应仍然持续存在。总之,我们的数据表明,虽然 BA.1 和 BA.2 突破感染拓宽了针对 SARS-CoV-2 刺突的免疫反应,但诱导的中和抗体反应仍然落后于病毒进化。